Abstract
An increasing number of studies have demonstrated that insulin-degrading enzyme (IDE) plays an essential role in both the degradation and its activity of β-amyloid (Aβ). Therefore, the regulation of IDE expression and/or modification of IDE-dependent actions are two emerging strategies for the treatment of Alzheimer’s disease (AD). We previously observed that geniposide, a novel agonist of glucagon-like peptide 1 receptor (GLP-1R), could attenuate Aβ-induced neurotoxicity by regulating the expression of IDE in primary cortical neurons. However, the signal transduction mechanisms underlying this effect were not elucidated. The present study, therefore examined and explored the cell signaling transduction and molecular mechanisms by which geniposide induces the expression of IDE in primary cortical neurons. The current study revealed that LY294002 (an inhibitor for phosphatidyl inositol 3-kinase, PI3K), PP1 (inhibitor for c-Src), GW9662 (antagonist for peroxisome proliferator-activated receptor γ, PPARγ), H89 (an inhibitor for protein kinase A, PKA) and AG1478 (an antagonist for epidermal growth factor receptor, EGFR) prohibited the up-regulation of IDE induced by geniposide in primary cortical neurons. Further, geniposide also enhanced the phosphorylation of PPARγ and accelerated the release of phosphorylated FoxO1 (forkhead box O1) from nuclear fraction to the cytosol. Moreover, geniposide directly activated the activity of IDE promoter in PC12 cells, which confirmed the presence of the GLP-1 receptor. Taken together, our findings reveal for the first time the cell signaling transduction pathway of geniposide regulating the expression of IDE in neurons.
Keywords: Alzheimer’s disease, β-amyloid, glucagon-like peptide 1, Insulin-degrading enzyme.
CNS & Neurological Disorders - Drug Targets
Title:Cell Signaling Mechanisms by which Geniposide Regulates Insulin- Degrading Enzyme Expression in Primary Cortical Neurons
Volume: 14 Issue: 3
Author(s): Yonglan Zhang, Zhining Xia, Jianhui Liu and Fei Yin
Affiliation:
Keywords: Alzheimer’s disease, β-amyloid, glucagon-like peptide 1, Insulin-degrading enzyme.
Abstract: An increasing number of studies have demonstrated that insulin-degrading enzyme (IDE) plays an essential role in both the degradation and its activity of β-amyloid (Aβ). Therefore, the regulation of IDE expression and/or modification of IDE-dependent actions are two emerging strategies for the treatment of Alzheimer’s disease (AD). We previously observed that geniposide, a novel agonist of glucagon-like peptide 1 receptor (GLP-1R), could attenuate Aβ-induced neurotoxicity by regulating the expression of IDE in primary cortical neurons. However, the signal transduction mechanisms underlying this effect were not elucidated. The present study, therefore examined and explored the cell signaling transduction and molecular mechanisms by which geniposide induces the expression of IDE in primary cortical neurons. The current study revealed that LY294002 (an inhibitor for phosphatidyl inositol 3-kinase, PI3K), PP1 (inhibitor for c-Src), GW9662 (antagonist for peroxisome proliferator-activated receptor γ, PPARγ), H89 (an inhibitor for protein kinase A, PKA) and AG1478 (an antagonist for epidermal growth factor receptor, EGFR) prohibited the up-regulation of IDE induced by geniposide in primary cortical neurons. Further, geniposide also enhanced the phosphorylation of PPARγ and accelerated the release of phosphorylated FoxO1 (forkhead box O1) from nuclear fraction to the cytosol. Moreover, geniposide directly activated the activity of IDE promoter in PC12 cells, which confirmed the presence of the GLP-1 receptor. Taken together, our findings reveal for the first time the cell signaling transduction pathway of geniposide regulating the expression of IDE in neurons.
Export Options
About this article
Cite this article as:
Zhang Yonglan, Xia Zhining, Liu Jianhui and Yin Fei, Cell Signaling Mechanisms by which Geniposide Regulates Insulin- Degrading Enzyme Expression in Primary Cortical Neurons, CNS & Neurological Disorders - Drug Targets 2015; 14 (3) . https://dx.doi.org/10.2174/1871527314666141229110156
DOI https://dx.doi.org/10.2174/1871527314666141229110156 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index To Volume 2
Current Cardiology Reviews What Can Imaging Reveal about Obesity and the Brain?
Current Alzheimer Research Readjusting the Glucocorticoid Balance: An Opportunity for Modulators of 11β -Hydroxysteroid Dehydrogenase Type 1 Activity?
Endocrine, Metabolic & Immune Disorders - Drug Targets The Therapeutic Potential of Differentiated Lung Cells from Embryonic Stem Cells in Lung Diseases
Current Stem Cell Research & Therapy The Vascular Compartments of Neovascularization: Spotlight on the Microcirculation
Current Pharmaceutical Biotechnology Regulation of Angiogenesis and Angiogenic Factors by Cardiovascular Medications
Current Pharmaceutical Design Biological Active Peptides from Marine Sources Related to Gut Hormones
Current Protein & Peptide Science Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Tissue Factor and Hypertension
Current Hypertension Reviews Gene Polymorphism of Angiotensin II Type 1 and Type 2 Receptors
Current Pharmaceutical Design Lifestyle, Maternal Nutrition and Healthy Pregnancy
Current Vascular Pharmacology Role of Heme Oxygenases in Cardiovascular Syndromes and Co-morbidities
Current Pharmaceutical Design Epidemiology, Prognosis and Prevention of Non-Traumatic Intracerebral Hemorrhage
Current Pharmaceutical Design Cryptic Peptides from Collagen: A Critical Review
Protein & Peptide Letters Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Estimated Arterial Stiffness and Prediction of Vascular Aging: The Rising of a New Era
Current Pharmaceutical Design Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and its Neuroprotective Effects in Mice After Intracranial Hemorrhage
CNS & Neurological Disorders - Drug Targets Pulmonary Hypertension and Lung Transplantation
Current Hypertension Reviews